Cited by 384Microbial Natural Products and BiosynthesisMarine Sponges and Natural ProductsSeaweed-derived Bioactive Compounds

Immense essence of excellence: Marine microbial bioactive compounds

Open access
Bhatnagar, Ira, Kim, Se-Kwon·2010·Marine Drugs

Abstract

Oceans have borne most of the biological activities on our planet. A number of biologically active compounds with varying degrees of action, such as anti-tumor, anti-cancer, anti-microtubule, anti-proliferative, cytotoxic, photo protective, as well as antibiotic and antifouling properties, have been isolated to date from marine sources. The marine environment also represents a largely unexplored source for isolation of new microbes (bacteria, fungi, actinomycetes, microalgae-cyanobacteria and diatoms) that are potent producers of bioactive secondary metabolites. Extensive research has been done to unveil the bioactive potential of marine microbes (free living and symbiotic) and the results are amazingly diverse and productive. Some of these bioactive secondary metabolites of microbial origin with strong antibacterial and antifungal activities are being intensely used as antibiotics and may be effective against infectious diseases such as HIV, conditions of multiple bacterial infections (penicillin, cephalosporines, streptomycin, and vancomycin) or neuropsychiatric sequelae. Research is also being conducted on the general aspects of biophysical and biochemical properties, chemical structures and biotechnological applications of the bioactive substances derived from marine microorganisms, and their potential use as cosmeceuticals and nutraceuticals. This review is an attempt to consolidate the latest studies and critical research in this field, and to showcase the immense competence of marine microbial flora as bioactive metabolite producers. In addition, the present review addresses some effective and novel approaches of procuring marine microbial compounds utilizing the latest screening strategies of drug discovery.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/md8102673

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Salinosporamide A is in phase I clinical trials.

    “Salinosporamide A, a novel long-lasting proteasome inhibitor isolated from a marine bacterium Salinispora tropica [230] in phase I clinical trials, has more efficacy against a wider range of hematologic malignancies and many solid tumor models, and less cytotoxicity to normal cells (Figure 8) [101].”

    From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [101]

  • Salinosporamide A has less cytotoxicity to normal cells.

    “Salinosporamide A, a novel long-lasting proteasome inhibitor isolated from a marine bacterium Salinispora tropica [230] in phase I clinical trials, has more efficacy against a wider range of hematologic malignancies and many solid tumor models, and less cytotoxicity to normal cells (Figure 8) [101].”

    From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [101]

  • Tasidotin and Soblidotin are promising anticancer agents.

    “Tasidotin, Synthadotin (ILX-651), derived from a marine bacterium in phase II clinical trials, and Soblidotin (TZT 1027), the bacterial peptide of marine origin in phase III clinical trials, are promising anticancer agents [101].”

    From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [101]

  • Soblidotin (TZT 1027) is in phase III clinical trials.

    “Tasidotin, Synthadotin (ILX-651), derived from a marine bacterium in phase II clinical trials, and Soblidotin (TZT 1027), the bacterial peptide of marine origin in phase III clinical trials, are promising anticancer agents [101].”

    From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [101]

  • Tasidotin (ILX-651) is in phase II clinical trials.

    “Tasidotin, Synthadotin (ILX-651), derived from a marine bacterium in phase II clinical trials, and Soblidotin (TZT 1027), the bacterial peptide of marine origin in phase III clinical trials, are promising anticancer agents [101].”

    From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [101]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 1

  1. [32]CORHH: Committee on the Ocean’s Role in Human Health, National Research Council Monsoons to Microbes: Understanding the Ocean's Role in Human Health The National Academies Press Washington, D.C., USA 1999 78 25101424

Cited by

Sorted by citations

Authors
Bhatnagar, I., & Kim, S.-K.
Affiliations
Pukyong National University (KR)
Corresponding author
Kim, Se-Kwon
Venue
Marine Drugs
Publisher
MDPI AG
Published
2010-10-15
Volume
8
Issue
10
Pages
2673-2701
ISSN
1660-3397 (ISSN-L)
OpenAlex
W2029997716
Cited by
384
References
124
Citations by year
2026: 12 · 2025: 13 · 2024: 21 · 2023: 23 · 2022: 28 · 2021: 18 · 2020: 39 · 2019: 26 · 2018: 25 · 2017: 26 · 2016: 32 · 2015: 28 · 2014: 30 · 2013: 23 · 2012: 27
FWCI
2.25
Type
journal article
Language
en
Open access
Locations
  • Marine Drugs (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology › Microbial Natural Products and Biosynthesis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Marine Sponges and Natural Products
  • Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Seaweed-derived Bioactive Compounds
Keywords
marine microorganisms, bioactive secondary metabolites, marine natural products, antibacterial agents, antifungal agents, anticancer agents, marine bacteria, actinomycetes, cyanobacteria, diatoms, microbial symbionts, drug discovery screening, cosmeceuticals, nutraceuticals
MeSH terms
Cyanobacteria, Animals, Anti-Bacterial Agents, Antifungal Agents, Antineoplastic Agents, Bacteria, Clinical Trials as Topic, Fungi, Seawater, Symbiosis, Diatoms, Drug Discovery, Microalgae, Aquatic Organisms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review